WoodTrust Financial Corp Cuts Holdings in Pfizer Inc. (NYSE:PFE)

WoodTrust Financial Corp lowered its position in Pfizer Inc. (NYSE:PFE) by 15.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 276,314 shares of the biopharmaceutical company’s stock after selling 49,056 shares during the period. Pfizer comprises approximately 1.0% of WoodTrust Financial Corp’s investment portfolio, making the stock its 26th biggest position. WoodTrust Financial Corp’s holdings in Pfizer were worth $7,331,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of PFE. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $28,000. Gladius Capital Management LP lifted its position in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares in the last quarter. Noble Wealth Management PBC acquired a new stake in Pfizer in the 4th quarter valued at $31,000. Finally, Sierra Ocean LLC purchased a new stake in Pfizer in the 4th quarter worth $34,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE stock opened at $25.72 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $145.73 billion, a PE ratio of 18.24, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The firm’s 50-day moving average is $26.32 and its two-hundred day moving average is $27.28. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.10 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.69%. Pfizer’s dividend payout ratio is currently 121.99%.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on PFE. Guggenheim reaffirmed a “buy” rating and set a $33.00 price objective on shares of Pfizer in a report on Monday, February 10th. UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.